Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient

Tumor Biology

Volumn 37, Issue 3, 2016, Pages 4041-4052

  Cavalloni, Giuliana ^a   Peraldo Neia, Caterina ^a   Varamo, Chiara ^b   Casorzo, Laura ^a   Dell’Aglio, Carmine ^a   Bernabei, Paola ^a   Chiorino, Giovanna ^c   Aglietta, Massimo ^a,b   Leone, Francesco ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Laboratory of Cancer Genomics   (Italy)

Author keywords

In vitro model; Intrahepatic cholangiocarcinoma; New cell line

Indexed keywords

ALPHA6 INTEGRIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD133 ANTIGEN; CD24 ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 7; EPITHELIAL CELL ADHESION MOLECULE; HEPATOCYTE NUCLEAR FACTOR 3BETA; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; KRAS PROTEIN, HUMAN; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL LINE; CARCINOGENICITY; CELL ISOLATION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; ITALIAN (CITIZEN); KARYOTYPING; MOLECULAR PATHOLOGY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BILE DUCT TUMOR; CANCER TRANSPLANTATION; CARCINOGEN TESTING; CELL MOTION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; ITALY; MIDDLE AGED; MISSENSE MUTATION; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BILE DUCT NEOPLASMS; CARCINOGENICITY TESTS; CELL LINE, TUMOR; CELL MOVEMENT; CHOLANGIOCARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; ITALY; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84944937544     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4215-3     Document Type: Article

References (47)

1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–29.
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.
3. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3:33–42.
4. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci. 2010;101:579–85.
5. Poomphakwaen K, Promthet S, Kamsa-Ard S, Vatanasapt P, Chaveepojnkamjorn W, Klaewkla J, et al. Risk factors for cholangiocarcinoma in khon kaen, thailand: a nested case–control study. Asian Pac J Cancer Prev. 2009;10:251–8.
6. Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8.
7. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in japan. Br J Cancer. 2010;103:469–74.
8. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, et al. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007;4, e201.
9. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–64.
10. Zhou Y, Zhao Y, Li B, Huang J, Wu L, Xu D, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012;12:289.
11. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis c virus-related cirrhosis. Cancer. 2000;88:2471–7.
12. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the united states: a case–control study. Gastroenterology. 2005;128:620–6.
13. Ma S, Hu L, Huang XH, Cao LQ, Chan KW, Wang Q, et al. Establishment and characterization of a human cholangiocarcinoma cell line. Oncol Rep. 2007;18:1195–200.
14. Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (kku-100). World J Gastroenterol. 2005;11:3392–7.
15. Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer. 2002;87:187–93.
16. Katoh H, Shinbo T, Otagiri H, Saitoh M, Saitoh T, Ishizawa S, et al. [character of a human cholangiocarcinoma chgs, serially transplanted to nude mice]. Hum Cell. 1988;1:101–5.
17. Jiao W, Yakushiji H, Kitajima Y, Ogawa A, Miyazaki K. Establishment and characterization of human hilar bile duct carcinoma cell line and cell strain. J Hepatobiliary Pancreat Surg. 2000;7:417–25.
18. Yamada N, Chung YS, Arimoto Y, Sawada T, Seki S, Sowa M. Establishment of a new human extrahepatic bile duct carcinoma cell line (ocuch-lm1) and experimental liver metastatic model. Br J Cancer. 1995;71:543–8.
19. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, tfk-1. Tohoku J Exp Med. 1995;177:61–71.
20. Yoshida K, Tomizawa H, Ota T, Nagashima T, Kikuchi H, Watanabe H, et al. [Establishment and characterization of human cholaginocarcinoma, MEC, producing carbohydrate antigen 19–9]. Hum Cell. 1990;3:346–51.
21. Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med (Berl). 1988;188:367–75.
22. Ghosh M, Koike N, Tsunoda S, Hirano T, Kaul S, Kashiwagi H, et al. Characterization and genetic analysis in the newly established human bile duct cancer cell lines. Int J Oncol. 2005;26:449–56.
23. Takiyama I, Terashima M, Ikeda K, Kawamura H, Kashiwaba M, Tamura G, et al. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (ICBD-1). Oncol Rep. 1998;5:463–7.
24. Yano H, Maruiwa M, Iemura A, Mizoguchi A, Kojiro M. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC). Cancer. 1992;69:1664–73.
25. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, et al. Biliary adenocarcinoma characterisation of three new human tumor cell lines. J Hepatol. 1985;1:579–96.
26. Kim DG, Park SY, You KR, Lee GB, Kim H, Moon WS, et al. Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding. Genes Chromosom Cancer. 2001;30:48–56.
27. Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S, Pausawasdi A. Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pac J Allergy Immunol. 1991;9:153–7.
28. Yamaguchi N, Morioka H, Ohkura H, Hirohashi S, Kawai K. Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J Natl Cancer Inst. 1985;75:29–35.
29. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-t1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol. 1989;25:503–10.
30. Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosom Cancer. 1990;2:300–10.
31. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer. 1992;52:252–60.
32. Iemura A, Maruiwa M, Yano H, Kojiro M. A new human cholangiocellular carcinoma cell line (KMC-1). J Hepatol. 1992;15:288–98.
33. Peraldo-Neia C, Cavalloni G, Soster M, Gammaitoni L, Marchiò S, Sassi F, et al. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer. 2014;14:918.
34. Shaffer LG, Mc Gowan-Jordan J, Shmid M: Iscn. An international system for human cytogenetic nomenclature. Basel, Swizterland, Karger Medical and Scientific Publishers, 2013
35. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.
36. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.
37. Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology. 2011;54:2159–72.
38. Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, et al. Antitumor activity of src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012;11:1528–38.
39. Malaguarnera G, Giordano M, Paladina I, Rando A, Uccello M, Basile F, et al. Markers of bile duct tumors. World J Gastrointest Oncol. 2011;3:49–59.
40. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R, AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42:490–5.
41. Rowehl RA, Burke S, Bialkowska AB, Pettet DW, Rowehl L, Li E, et al. Establishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cells. PLoS One. 2014;9, e99091.
42. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–28.
43. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells—what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512.
44. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767–75.
45. Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2001;130:22–8.
46. Uhm KO, Park YN, Lee JY, Yoon DS, Park SH. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2005;157:37–41.
47. Rijken AM, Hu J, Perlman EJ, Morsberger LA, Long P, Kern SE, et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosom Cancer. 1999;26:185–91.